Medical School · Year 3 · Neurology · includes a quiz and discussion video

Seminar 06: Multiple Sclerosis and Demyelinating Diseases

Year 3: Neurology Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Describe the pathophysiology of multiple sclerosis
2. Recognize clinical presentations of MS
3. Apply diagnostic criteria for multiple sclerosis
4. Manage acute MS exacerbations
5. Select appropriate disease-modifying therapies
6. Differentiate MS from other demyelinating disorders

Seminar Outline

I. Multiple Sclerosis Overview

Multiple sclerosis represents the most common immune-mediated inflammatory demyelinating disease of the central nervous system and a leading cause of non-traumatic neurological disability in young adults. The prevalence in the United States approaches one million individuals, with women affected approximately three times more commonly than men. The typical age of onset falls between twenty and forty years, though pediatric and late-onset cases occur. Geographic distribution demonstrates a latitude gradient with higher prevalence in regions farther from the equator, suggesting environmental factors including vitamin D exposure contribute to disease risk. Additional established risk factors include genetic susceptibility, particularly HLA-DRB1*15:01, Epstein-Barr virus infection, adolescent obesity, and cigarette smoking.

The pathophysiology of multiple sclerosis involves complex interactions between the immune system and the central nervous system resulting in inflammation, demyelination, and neurodegeneration. Both T-cell-mediated and B-cell-mediated mechanisms contribute to the inflammatory process. Autoreactive lymphocytes enter the central nervous system across a disrupted blood-brain barrier and orchestrate an inflammatory response targeting myelin and oligodendrocytes. Acute inflammatory plaques demonstrate perivascular inflammation, myelin breakdown, and variable degrees of axonal injury. Chronic plaques show demyelination, astrogliosis, and axonal loss. The predilection for particular central nervous system locations including periventricular white matter, juxtacortical regions, infratentorial structures, and spinal cord reflects the pathophysiology and informs diagnostic criteria.

Multiple sclerosis exhibits several clinical phenotypes with important prognostic and therapeutic implications. Relapsing-remitting multiple sclerosis characterizes approximately eighty-five percent of patients at disease onset and features discrete clinical attacks followed by periods of remission with complete or partial recovery. Secondary progressive multiple sclerosis develops in a substantial proportion of relapsing-remitting patients over time, characterized by gradual accumulation of disability independent of relapses. Primary progressive multiple sclerosis, affecting approximately ten to fifteen percent of patients, manifests as gradual neurological decline from disease onset without distinct relapses. The progressive relapsing phenotype describes primary progressive disease with superimposed relapses. Recognizing the clinical phenotype guides treatment selection, as different disease-modifying therapies demonstrate efficacy in different disease stages.

Several prognostic factors inform counseling about disease course and outcome. Female sex confers relatively better prognosis than male sex. Younger age at onset, particularly onset in childhood or adolescence, associates with better short-term prognosis though longer lifetime disease duration. Initial presentation with sensory symptoms or optic neuritis carries more favorable prognosis than motor, cerebellar, or sphincter dysfunction at onset. Complete recovery from initial relapse predicts better outcomes than incomplete recovery. Higher lesion burden on initial magnetic resonance imaging and more frequent early relapses predict more aggressive disease course. The advent of disease-modifying therapy has substantially improved prognosis, with early treatment initiation associated with better long-term outcomes, underscoring the importance of early diagnosis.

<image>Panel A: Epidemiology map showing latitude gradient of multiple sclerosis prevalence with environmental and genetic risk factors. Panel B: Pathophysiology diagram depicting T-cell and B-cell entry across blood-brain barrier, acute plaque formation with inflammation and demyelination, and chronic plaque with axonal loss. Panel C: Clinical phenotypes diagram showing relapsing-remitting, secondary progressive, primary progressive, and progressive-relapsing courses over time. Panel D: Prognostic factors table organizing favorable and unfavorable features for disease course prediction.</image>

II. Clinical Presentations

The clinical manifestations of multiple sclerosis reflect the diverse locations of demyelinating lesions throughout the central nervous system. Optic neuritis represents one of the most recognizable presenting syndromes, occurring as the initial manifestation in approximately twenty percent of patients. Patients experience subacute monocular vision loss developing over hours to days, often accompanied by pain exacerbated by eye movement. Visual field testing typically reveals central scotoma, and examination demonstrates relative afferent pupillary defect. Vision typically recovers substantially over weeks, though residual color desaturation and contrast sensitivity impairment may persist. Sensory symptoms constitute another common presentation, with patients describing numbness, tingling, or band-like sensations affecting limbs or trunk. Lhermitte's sign, an electric shock-like sensation radiating down the spine or into limbs with neck flexion, reflects cervical spinal cord involvement and occurs in approximately one-third of patients at some point.

Motor symptoms manifest as weakness, stiffness, or spasticity affecting one or more limbs. Corticospinal tract involvement produces upper motor neuron pattern weakness with associated hyperreflexia, spasticity, and extensor plantar responses. Cerebellar involvement produces ataxia affecting gait and limbs, dysmetria, intention tremor, and scanning dysarthria. Brainstem syndromes produce diverse manifestations depending on the structures affected. Internuclear ophthalmoplegia, resulting from medial longitudinal fasciculus lesions, produces impaired adduction of the ipsilateral eye with nystagmus in the abducting contralateral eye during horizontal gaze, and when bilateral, is highly suggestive of multiple sclerosis in a young adult. Vertigo, diplopia, facial numbness or weakness, and dysarthria may all result from brainstem demyelination.

Bladder dysfunction affects the majority of multiple sclerosis patients at some point and significantly impacts quality of life. Detrusor hyperreflexia produces urgency, frequency, and urge incontinence, while detrusor-sphincter dyssynergia causes hesitancy, incomplete emptying, and retention. Many patients experience mixed patterns. Fatigue represents the most common symptom reported by multiple sclerosis patients, often disproportionate to objective disability and incompletely explained by sleep disturbance, depression, or medication effects. Cognitive impairment affects approximately half of patients, typically manifesting as slowed processing speed, impaired memory retrieval, and executive dysfunction rather than aphasia or cortical dementia patterns. Depression occurs in approximately half of patients over the disease course and requires active screening and treatment.

Uhthoff phenomenon describes temporary worsening of neurological symptoms with elevated body temperature, whether from exercise, hot weather, fever, or hot bath. This phenomenon results from temperature-dependent conduction block in demyelinated axons, where even small temperature elevations impair already compromised saltatory conduction. Importantly, Uhthoff phenomenon represents a pseudo-relapse rather than a true exacerbation and resolves with cooling without requiring corticosteroid treatment. Understanding this phenomenon helps distinguish true relapses requiring treatment from transient symptom fluctuations. Physical examination in multiple sclerosis may reveal combinations of upper motor neuron signs, cerebellar signs, sensory level or dissociated sensory loss, and eye movement abnormalities reflecting the multifocal nature of central nervous system involvement.

<image>Panel A: Optic neuritis presentation showing monocular vision loss, periocular pain with eye movement, relative afferent pupillary defect testing, and typical visual field defect. Panel B: Internuclear ophthalmoplegia illustration demonstrating medial longitudinal fasciculus lesion location, impaired adduction, and nystagmus in abducting eye. Panel C: Common symptom frequency chart showing relative prevalence of fatigue, sensory symptoms, motor symptoms, bladder dysfunction, and cognitive impairment. Panel D: Uhthoff phenomenon explanation showing temperature-dependent conduction block mechanism and distinction from true relapse.</image>

III. Diagnosis of Multiple Sclerosis

The diagnosis of multiple sclerosis requires demonstration of inflammatory demyelinating disease disseminated in both space and time, with exclusion of alternative diagnoses. The McDonald criteria, most recently revised in 2017, provide the diagnostic framework integrating clinical, imaging, and laboratory data. For patients presenting with two or more clinical attacks and objective evidence of two or more lesions, the diagnosis can be established on clinical grounds alone without additional testing. However, most patients present with fewer attacks or lesions, requiring demonstration of dissemination through additional criteria. The concept of dissemination in space reflects the requirement that multiple areas of the central nervous system must be involved, while dissemination in time requires evidence that the disease process is ongoing rather than a single monophasic event.

Dissemination in space is satisfied by the presence of one or more T2-hyperintense lesions in at least two of four characteristic central nervous system locations: periventricular white matter, juxtacortical or cortical gray matter, infratentorial regions including brainstem and cerebellum, and spinal cord. This anatomical distribution pattern reflects the characteristic predilection of multiple sclerosis lesions and helps distinguish the disease from other conditions affecting white matter. Periventricular lesions oriented perpendicular to the ventricular surface, termed Dawson's fingers, represent a characteristic radiological appearance. The clinical attack itself may substitute for one anatomical location if referable to a characteristic region.

Dissemination in time is satisfied by the simultaneous presence of gadolinium-enhancing and non-enhancing lesions on a single magnetic resonance imaging scan, reflecting lesions of different ages, or by the development of new T2-hyperintense or gadolinium-enhancing lesions on follow-up imaging compared to a baseline scan. The 2017 revision introduced an important change allowing cerebrospinal fluid-specific oligoclonal bands to substitute for dissemination in time, enabling earlier diagnosis in patients presenting with a clinically isolated syndrome and dissemination in space. This change recognizes that oligoclonal bands represent evidence of ongoing intrathecal immune activity supporting a diagnosis of multiple sclerosis rather than a monophasic process.

Primary progressive multiple sclerosis has distinct diagnostic criteria reflecting its different clinical phenotype. Diagnosis requires one year of progressive neurological deterioration plus at least two of the following three criteria: dissemination in space in the brain evidenced by at least one T2-hyperintense lesion in a characteristic location, dissemination in space in the spinal cord evidenced by at least two T2-hyperintense lesions, or positive cerebrospinal fluid demonstrated by oligoclonal bands or elevated immunoglobulin G index. Throughout the diagnostic process, alternative diagnoses must be excluded through appropriate evaluation based on the clinical presentation, as numerous conditions can mimic multiple sclerosis both clinically and radiologically.

<image>Panel A: McDonald criteria flowchart showing diagnostic requirements based on number of clinical attacks and lesions, with pathways to demonstrating DIS and DIT. Panel B: Dissemination in space diagram showing the four characteristic CNS locations with representative MRI lesion appearances. Panel C: Dissemination in time illustration showing gadolinium-enhancing active lesion versus non-enhancing chronic lesion on the same scan. Panel D: Primary progressive MS diagnostic criteria diagram with required progression and supporting features.</image>

IV. Diagnostic Testing

Magnetic resonance imaging represents the most important paraclinical tool in multiple sclerosis diagnosis and monitoring. The standard protocol includes T2-weighted and fluid-attenuated inversion recovery sequences to detect white matter lesions, T1-weighted sequences before and after gadolinium contrast to identify active inflammation, and imaging of both brain and spinal cord. Characteristic brain lesions appear as ovoid T2-hyperintense foci in periventricular, juxtacortical, and infratentorial white matter, with periventricular lesions often perpendicular to the ventricles. Gadolinium enhancement indicates blood-brain barrier breakdown at sites of active inflammation, typically lasting weeks to a few months. T1-hypointense lesions, termed black holes, represent areas of more severe tissue damage including axonal loss and correlate with disability accumulation.

Cerebrospinal fluid analysis provides supportive diagnostic information, though a lumbar puncture is not mandatory when imaging criteria are met. Oligoclonal bands represent immunoglobulin G synthesized intrathecally and detected as discrete bands on isoelectric focusing that are present in cerebrospinal fluid but absent in paired serum samples. These bands are present in eighty-five to ninety-five percent of patients with established multiple sclerosis and reflect the ongoing immune response within the central nervous system. The immunoglobulin G index, calculated from cerebrospinal fluid and serum albumin and immunoglobulin G concentrations, provides another measure of intrathecal immunoglobulin synthesis. Cerebrospinal fluid typically shows mild lymphocytic pleocytosis, generally below fifty cells per microliter, and mildly elevated protein, usually below one hundred milligrams per deciliter. More marked abnormalities should prompt consideration of alternative diagnoses.

Additional diagnostic tests serve specific roles in the evaluation. Visual evoked potentials assess conduction through the optic pathway and may demonstrate prolonged P100 latency indicating subclinical optic nerve demyelination even in patients without history of optic neuritis. Optical coherence tomography provides high-resolution imaging of the retinal nerve fiber layer and ganglion cell layer, with thinning indicating prior optic nerve injury. Testing for neuromyelitis optica spectrum disorder antibodies, specifically aquaporin-4 immunoglobulin G, should be performed when clinical or radiological features suggest this diagnosis, particularly longitudinally extensive transverse myelitis or bilateral or recurrent optic neuritis. Myelin oligodendrocyte glycoprotein antibody testing identifies a distinct entity with overlapping features.

The differential diagnosis of multiple sclerosis encompasses numerous conditions that may produce multifocal central nervous system white matter abnormalities. Neuromyelitis optica spectrum disorder, discussed in detail subsequently, requires differentiation given its distinct treatment requirements. Acute disseminated encephalomyelitis presents with monophasic multifocal demyelination, typically following infection or vaccination. Systemic inflammatory diseases including sarcoidosis and systemic lupus erythematosus may involve the central nervous system. Central nervous system vasculitis produces white matter changes requiring angiographic or biopsy confirmation. Central nervous system lymphoma may mimic tumefactive demyelination. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy presents with migraine, stroke, dementia, and white matter abnormalities in patients with family history. Infectious etiologies including neuroborreliosis and progressive multifocal leukoencephalopathy require consideration in appropriate contexts.

<image>Panel A: MRI protocol showing T2/FLAIR brain sequences, T1 pre- and post-gadolinium, and spinal cord imaging with characteristic lesion appearances. Panel B: CSF analysis interpretation showing oligoclonal band detection by isoelectric focusing and IgG index calculation. Panel C: Visual evoked potentials showing prolonged P100 latency in demyelinated optic pathway compared to normal. Panel D: Differential diagnosis table organizing conditions mimicking MS by category with distinguishing features.</image>

V. Acute Relapse Management

A relapse, also termed an exacerbation or attack, is defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis, lasting at least twenty-four hours, occurring at least thirty days after the onset of a prior event, and not explained by fever, infection, or other metabolic disturbance. The requirement to exclude confounding factors is particularly important, as infections, especially urinary tract infections, commonly precipitate transient symptom worsening through the Uhthoff mechanism without representing true inflammatory relapses. When patients report symptom worsening, clinical evaluation should include assessment for infection with urinalysis and consideration of other systemic illness. True relapses reflect new or reactivated central nervous system inflammation and may warrant treatment to hasten recovery.

High-dose corticosteroids represent the standard treatment for acute multiple sclerosis relapses causing functionally significant symptoms. The typical regimen consists of intravenous methylprednisolone one thousand milligrams daily for three to five days. Evidence suggests that high-dose oral corticosteroids, such as prednisone one thousand two hundred fifty milligrams daily, achieve comparable bioavailability and efficacy, offering a convenient outpatient alternative for patients without severe symptoms requiring hospitalization. Corticosteroid treatment accelerates recovery from relapse, shortening the duration of symptoms, but does not appear to influence the ultimate degree of recovery or alter long-term disease course. Therefore, treatment is typically reserved for relapses producing significant functional impairment rather than minor sensory symptoms that do not affect daily function.

Plasma exchange, or plasmapheresis, provides an option for patients experiencing severe relapses that fail to respond to corticosteroid treatment. The treatment involves removal and replacement of plasma to eliminate circulating antibodies and other inflammatory mediators. A typical course consists of five to seven exchanges performed over ten to fourteen days. Approximately forty to fifty percent of steroid-refractory patients demonstrate significant improvement with plasma exchange, though response rates vary by symptom type. Plasmapheresis is generally considered for severe attacks producing significant disability, particularly acute severe motor or visual impairment, when corticosteroids have not produced adequate recovery. Early initiation may improve outcomes, supporting relatively prompt consideration when steroid response is inadequate.

Pseudo-relapses describe temporary symptom worsening in the context of physiological stressors that do not represent new inflammatory activity and do not require immunosuppressive treatment. Urinary tract infection represents the most common trigger, and screening with urinalysis should be routine when patients report symptom worsening. Fever from any cause may unmask or worsen symptoms through temperature-dependent conduction impairment. Heat exposure, whether environmental or from exercise, produces similar effects through the Uhthoff mechanism. Physical or emotional stress may transiently worsen symptoms. Management of pseudo-relapses focuses on identifying and treating the underlying trigger, providing reassurance about the transient nature of worsening, and implementing cooling strategies when heat exposure is implicated. Corticosteroid treatment is not indicated and would expose patients to unnecessary adverse effects.

<image>Panel A: Relapse definition diagram showing required features including symptom duration, interval from prior event, and exclusion of confounding factors. Panel B: Corticosteroid treatment comparison showing IV methylprednisolone versus high-dose oral regimens with expected outcomes. Panel C: Plasma exchange protocol showing indication for steroid-refractory severe relapses, typical schedule, and expected response rates. Panel D: Pseudo-relapse identification flowchart showing common triggers and management approach distinct from true relapse treatment.</image>

VI. Disease-Modifying Therapies

Disease-modifying therapies for multiple sclerosis reduce relapse frequency, slow disability accumulation, and decrease new lesion formation on magnetic resonance imaging. The therapeutic landscape has expanded dramatically over recent decades, with currently available agents spanning injectable, oral, and infusion formulations with varying efficacy and safety profiles. Injectable therapies include interferon beta preparations and glatiramer acetate, representing the earliest disease-modifying therapies with extensive long-term safety data. Interferon beta acts through immunomodulatory mechanisms including shifting cytokine profiles and reducing blood-brain barrier permeability. Common side effects include injection site reactions and flu-like symptoms that often improve over time. Glatiramer acetate, a synthetic polypeptide, modulates the immune response through mechanisms including induction of regulatory T cells. These injectable agents reduce relapse rates by approximately thirty percent compared to placebo.

Oral therapies offer convenience that may improve adherence for patients reluctant to use injectable medications. Fingolimod was the first oral agent approved for multiple sclerosis and acts as a sphingosine-1-phosphate receptor modulator, trapping lymphocytes in lymph nodes and preventing their migration to the central nervous system. First-dose cardiac monitoring is required due to transient bradycardia. Macular edema requires ophthalmologic surveillance. Dimethyl fumarate activates the Nrf2 pathway with antioxidant and anti-inflammatory effects. Gastrointestinal symptoms and flushing are common initially but often improve with continued use. Rare cases of progressive multifocal leukoencephalopathy have occurred, primarily in the setting of prolonged lymphopenia. Teriflunomide inhibits pyrimidine synthesis in rapidly proliferating lymphocytes. Its long half-life and teratogenicity require special considerations for women of childbearing potential.

Infusion therapies generally demonstrate higher efficacy and are increasingly used for patients with active disease. Natalizumab, a monoclonal antibody targeting alpha-4 integrin, prevents lymphocyte migration across the blood-brain barrier and demonstrates robust efficacy for relapse reduction. The risk of progressive multifocal leukoencephalopathy from JC virus reactivation requires stratification based on JC virus antibody status, prior immunosuppression, and treatment duration. Ocrelizumab, an anti-CD20 monoclonal antibody, depletes B cells and represents the first agent approved for primary progressive multiple sclerosis in addition to relapsing disease. Alemtuzumab, targeting CD52, produces profound lymphocyte depletion with durable efficacy but carries risks of secondary autoimmunity affecting thyroid, platelets, and kidneys requiring prolonged monitoring. Rituximab, also targeting CD20, is widely used off-label with substantial supporting evidence.

Treatment selection involves balancing efficacy, safety, tolerability, and patient factors. Historically, therapy followed an escalation approach starting with moderate-efficacy agents and advancing to higher-efficacy treatments after breakthrough disease. Current approaches increasingly favor early high-efficacy treatment, particularly for patients with active or aggressive disease, recognizing that early disease control may prevent irreversible neurological damage. Factors influencing treatment choice include disease activity, patient age and comorbidities, reproductive planning, infection risk, and patient preferences regarding route of administration and monitoring requirements. JC virus serostatus influences natalizumab risk stratification. Pregnancy planning requires attention to medication washout periods and teratogenicity. Vaccinations should be completed before initiating B-cell-depleting therapies given blunted vaccine responses during treatment.

<image>Panel A: Injectable therapy comparison showing interferon beta and glatiramer acetate mechanisms, administration, efficacy, and common side effects. Panel B: Oral therapy options table comparing fingolimod, dimethyl fumarate, and teriflunomide mechanisms, efficacy, and key safety considerations. Panel C: Infusion therapy efficacy and risk comparison for natalizumab, ocrelizumab, and alemtuzumab with monitoring requirements. Panel D: Treatment selection algorithm incorporating disease activity, patient factors, and risk stratification to guide therapy choice.</image>

VII. Symptom Management

Fatigue represents the most commonly reported symptom in multiple sclerosis, affecting the majority of patients and frequently cited as the most disabling symptom regardless of physical disability level. Non-pharmacological management forms the foundation of fatigue treatment, including energy conservation strategies, activity pacing, optimization of sleep hygiene, and regular aerobic exercise, which paradoxically improves energy despite acute exertion-related fatigue. Cooling vests and strategies may benefit patients whose fatigue is exacerbated by heat. Depression screening is important as depression contributes substantially to fatigue and may respond to targeted treatment. Pharmacological options include amantadine at one hundred milligrams twice daily, which provides modest benefit in some patients through unclear mechanisms. Modafinil and other wakefulness-promoting agents may help, particularly when daytime sleepiness accompanies fatigue. Amphetamine-based stimulants are sometimes used but carry abuse potential.

Spasticity, resulting from upper motor neuron involvement, commonly affects the lower extremities and contributes to gait difficulty, discomfort, and functional impairment. Physical therapy with stretching exercises forms the cornerstone of management, maintaining muscle length and preventing contractures. Baclofen, a GABA-B receptor agonist, represents the most commonly used oral medication, typically initiated at five milligrams two to three times daily and titrated to effect. Sedation and weakness from systemic effect on intact motor pathways may limit tolerability. Tizanidine, an alpha-2 adrenergic agonist, provides an alternative with more prominent sedation that may benefit patients with sleep disturbance. Severe spasticity refractory to oral medications may benefit from intrathecal baclofen delivered via implanted pump, providing high local concentrations with reduced systemic effects. Botulinum toxin injections address focal spasticity in specific muscle groups.

Bladder dysfunction affects most patients during their disease course and significantly impacts quality of life. Assessment begins with post-void residual measurement to distinguish between failure to store, failure to empty, or combined patterns. Detrusor hyperreflexia causing urgency and frequency responds to anticholinergic medications such as oxybutynin or tolterodine, or the beta-3 agonist mirabegron. Inadequate emptying with elevated residual volumes requires intermittent self-catheterization, which patients can generally learn to perform independently. OnabotullinumtoxinA injection into the detrusor muscle provides an option for refractory overactive bladder. Urological referral for urodynamic testing is appropriate for complex or refractory cases.

Multiple additional symptoms require attention in comprehensive multiple sclerosis care. Neuropathic pain responds to medications including gabapentin, pregabalin, and duloxetine. Depression should be actively screened for and treated with selective serotonin reuptake inhibitors and psychotherapy. Cognitive dysfunction may benefit from cognitive rehabilitation strategies though pharmacological options remain limited. Tremor in multiple sclerosis often proves refractory to medication, though trials of beta-blockers, clonazepam, and other agents may be attempted. Dalfampridine, a potassium channel blocker, improves walking speed in a subset of patients by enhancing conduction in demyelinated axons and represents the only medication specifically approved for walking impairment in multiple sclerosis. Sexual dysfunction, bowel dysfunction, and temperature sensitivity all warrant assessment and management as part of comprehensive care.

<image>Panel A: Fatigue management pyramid showing foundation of non-pharmacological approaches with pharmacological options for refractory cases. Panel B: Spasticity treatment ladder from stretching through oral medications to intrathecal baclofen and botulinum toxin for focal involvement. Panel C: Bladder dysfunction algorithm based on post-void residual measurement directing treatment toward anticholinergics, catheterization, or combined approaches. Panel D: Comprehensive symptom management checklist covering common MS symptoms with first-line interventions for each.</image>

VIII. Neuromyelitis Optica Spectrum Disorder

Neuromyelitis optica spectrum disorder represents an antibody-mediated inflammatory demyelinating disease that, while sharing some clinical features with multiple sclerosis, is pathophysiologically distinct and requires different treatment approaches. The disease is characterized by attacks of optic neuritis and transverse myelitis that are typically more severe than corresponding presentations in multiple sclerosis. Optic neuritis in neuromyelitis optica spectrum disorder frequently produces more severe visual loss and may affect both eyes simultaneously or sequentially over a short interval. Myelitis is characteristically longitudinally extensive, spanning three or more vertebral segments on magnetic resonance imaging, in contrast to the short-segment partial myelitis typical of multiple sclerosis. Additional core clinical features include area postrema syndrome presenting as intractable hiccups, nausea, and vomiting, and brainstem or diencephalic syndromes.

The discovery of aquaporin-4 immunoglobulin G antibody transformed understanding of neuromyelitis optica spectrum disorder, establishing it as a distinct autoimmune disease rather than a multiple sclerosis variant. Aquaporin-4 is a water channel highly expressed on astrocyte foot processes, and the pathogenic antibody targets these structures, producing astrocyte injury with secondary demyelination and inflammation. Testing for aquaporin-4 immunoglobulin G using cell-based assays provides high sensitivity and specificity. Seropositivity in the context of a core clinical syndrome establishes the diagnosis. Seronegative patients may still have neuromyelitis optica spectrum disorder if stringent clinical and radiological criteria are met, including specific attack characteristics and characteristic lesions. Brain magnetic resonance imaging is typically normal initially or shows atypical lesions distinct from multiple sclerosis, though brain lesions may develop over time.

Distinguishing neuromyelitis optica spectrum disorder from multiple sclerosis carries critical therapeutic implications. Many disease-modifying therapies effective for multiple sclerosis are ineffective for neuromyelitis optica spectrum disorder and may even worsen the disease. Interferon beta, natalizumab, and fingolimod have all been reported to exacerbate neuromyelitis optica spectrum disorder. Therefore, accurate diagnosis is essential before initiating disease-modifying therapy. Features favoring neuromyelitis optica spectrum disorder over multiple sclerosis include longitudinally extensive myelitis, severe optic neuritis with poor recovery, area postrema syndrome, aquaporin-4 antibody seropositivity, and brain magnetic resonance imaging that is normal or shows non-specific lesions. Features favoring multiple sclerosis include typical ovoid periventricular lesions, short-segment partial myelitis, oligoclonal bands in cerebrospinal fluid, and aquaporin-4 antibody seronegativity.

Treatment of neuromyelitis optica spectrum disorder focuses on acute attack management and long-term prevention of relapses. Acute attacks require high-dose intravenous corticosteroids, and plasma exchange should be considered early, particularly for severe attacks or those not responding promptly to steroids. Attack prevention relies on immunosuppressive therapies. Rituximab, an anti-CD20 monoclonal antibody producing B-cell depletion, has become widely used based on substantial observational evidence. Recently approved therapies specifically for neuromyelitis optica spectrum disorder include eculizumab, a complement inhibitor; inebilizumab, another anti-CD20 agent; and satralizumab, an interleukin-6 receptor inhibitor. These targeted therapies have demonstrated efficacy in randomized trials. Older immunosuppressants including azathioprine and mycophenolate mofetil remain options, particularly where newer agents are unavailable or unaffordable. Prognosis without treatment is generally worse than multiple sclerosis, with attacks causing cumulative stepwise disability, but effective prevention of relapses substantially improves outcomes.

<image>Panel A: NMOSD core clinical features showing severe optic neuritis, longitudinally extensive transverse myelitis on sagittal MRI, and area postrema syndrome. Panel B: Aquaporin-4 antibody pathophysiology illustration depicting antibody targeting astrocyte foot processes with secondary demyelination. Panel C: Side-by-side comparison table of NMOSD versus MS features including myelitis extent, optic neuritis severity, brain MRI, CSF findings, and antibody status. Panel D: NMOSD treatment algorithm showing acute management with steroids and plasma exchange, and relapse prevention options including rituximab and newly approved targeted therapies.</image>

IX. Other Demyelinating Disorders

Myelin oligodendrocyte glycoprotein antibody-associated disease has emerged as a distinct entity separate from both multiple sclerosis and aquaporin-4-positive neuromyelitis optica spectrum disorder. The pathogenic antibody targets myelin oligodendrocyte glycoprotein, a protein expressed on the outer surface of oligodendrocytes and myelin. Clinical presentations overlap with both multiple sclerosis and neuromyelitis optica spectrum disorder, including optic neuritis, transverse myelitis, and acute disseminated encephalomyelitis-like presentations with large, bilateral, poorly demarcated brain lesions. Optic neuritis in myelin oligodendrocyte glycoprotein antibody disease often involves the optic nerve anteriorly with visible disc edema, in contrast to the retrobulbar pattern typical of multiple sclerosis. The disease may follow a monophasic course in some patients, particularly children, while others experience relapses. Treatment approaches parallel neuromyelitis optica spectrum disorder, with corticosteroid responsiveness characteristic but often requiring prolonged tapers to prevent early relapse.

Acute disseminated encephalomyelitis represents a monophasic inflammatory demyelinating disorder that typically follows a viral infection or vaccination, most commonly affecting children though adults may be affected. Patients present with encephalopathy, which distinguishes the condition from multiple sclerosis and typical clinically isolated syndrome presentations, along with multifocal neurological deficits reflecting widespread central nervous system involvement. Magnetic resonance imaging demonstrates large, bilateral, poorly marginated lesions throughout the white matter, often involving deep gray matter structures and with relative sparing of periventricular regions. The distinction from a first attack of multiple sclerosis may be challenging, and some patients initially diagnosed with acute disseminated encephalomyelitis subsequently experience further events meeting criteria for multiple sclerosis. Treatment consists of high-dose intravenous corticosteroids, with plasma exchange or intravenous immunoglobulin for refractory cases.

Progressive multifocal leukoencephalopathy is an opportunistic infection caused by JC virus reactivation in immunocompromised patients. In the context of multiple sclerosis, this condition has become relevant due to its association with natalizumab therapy, particularly in patients who are JC virus antibody positive, have received prior immunosuppression, or have prolonged treatment duration exceeding two years. Presentation involves progressive focal neurological deficits reflecting subcortical white matter involvement, including cognitive changes, motor weakness, visual impairment, and ataxia. Brain magnetic resonance imaging demonstrates asymmetric white matter lesions that typically lack gadolinium enhancement and mass effect, distinguishing them from acute multiple sclerosis lesions. Diagnosis requires detection of JC virus DNA in cerebrospinal fluid by polymerase chain reaction or brain biopsy. Treatment centers on immune reconstitution, which in the setting of natalizumab involves discontinuing the medication and potentially accelerating drug clearance with plasma exchange. Mortality remains substantial despite intervention.

Osmotic demyelination syndrome, encompassing central pontine myelinolysis and extrapontine myelinolysis, results from rapid correction of chronic hyponatremia. The pathophysiology involves osmotic stress to oligodendrocytes and myelin as extracellular osmolality rises faster than cells can adapt, particularly affecting the pons due to its unique architecture. Patients typically present with neurological deterioration days after sodium correction, developing quadriparesis, dysarthria, dysphagia, and in severe cases locked-in syndrome with intact consciousness but inability to move or speak except through eye movements. Brain magnetic resonance imaging demonstrates characteristic T2-hyperintensity in the central pons, often with a trident or bat-wing shape, and potentially extrapontine involvement in basal ganglia and other structures. Prevention through slow sodium correction, limiting the rate of rise to ten to twelve milliequivalents per liter per day or less in patients with chronic hyponatremia, is far more effective than any available treatment for established disease. Prognosis is variable, with some patients achieving substantial recovery while others sustain permanent disability.

<image>Panel A: MOG antibody disease features showing anterior optic neuritis with disc edema, bilateral brain lesions, and comparison with MS and NMOSD antibody profiles. Panel B: ADEM presentation in child showing encephalopathy, multifocal deficits, and characteristic large bilateral poorly-defined MRI lesions. Panel C: PML imaging showing asymmetric white matter lesions without enhancement, with JC virus detection pathway and treatment approach. Panel D: Osmotic demyelination syndrome showing central pontine myelinolysis imaging pattern and prevention through controlled sodium correction rate.</image>

X. Special Considerations

Multiple sclerosis management in women of childbearing potential requires careful attention to the complex interactions between disease activity, disease-modifying therapy, and reproductive planning. Relapse rates decrease during pregnancy, particularly in the third trimester, likely related to the immunomodulatory state of pregnancy. However, relapse risk increases in the postpartum period, particularly in the first three months. Pre-conception counseling should address disease stabilization, with the goal of achieving stable disease on a treatment regimen compatible with pregnancy before conception. Most disease-modifying therapies require discontinuation before or upon confirmation of pregnancy, with specific washout periods depending on the medication. Glatiramer acetate and interferon beta may be continued during pregnancy if needed for disease control. Breastfeeding considerations include compatibility of specific medications with lactation and the potential protective effect of breastfeeding on postpartum relapse risk.

Radiologically isolated syndrome describes the incidental discovery of brain magnetic resonance imaging abnormalities meeting imaging criteria for multiple sclerosis dissemination in space in patients undergoing imaging for unrelated indications who have no history of clinical events attributable to demyelination. These patients have been found to develop clinically definite multiple sclerosis at rates of approximately thirty to fifty percent within ten years of discovery. Features associated with higher conversion risk include younger age, presence of gadolinium-enhancing lesions, spinal cord lesions, and cerebrospinal fluid oligoclonal bands. The management of radiologically isolated syndrome remains debated, with approaches ranging from observation with serial imaging to proactive treatment with disease-modifying therapy in high-risk patients. The recognition that brain lesions accumulate silently before and between clinical attacks in multiple sclerosis supports arguments for early intervention in appropriate cases.

Pediatric multiple sclerosis, accounting for approximately three to five percent of multiple sclerosis cases, presents unique diagnostic and management considerations. Children often have higher relapse rates early in the disease course compared to adults, though disability accumulation may be slower initially given greater neural plasticity and repair capacity. The differential diagnosis must include acute disseminated encephalomyelitis, which presents more commonly in children and may be difficult to distinguish from a first multiple sclerosis attack, particularly when encephalopathy is absent. Diagnostic criteria for pediatric multiple sclerosis incorporate similar principles to adult criteria with some modifications. Several disease-modifying therapies have been studied specifically in pediatric populations, with fingolimod and dimethyl fumarate approved for use in adolescents. Long-term prognosis in pediatric-onset disease reflects the longer disease duration, with patients reaching disability milestones at younger ages despite potentially slower progression rates.

Monitoring patients on disease-modifying therapy involves regular clinical assessment and surveillance imaging. Clinical evaluation every three to six months allows detection of subclinical relapses and assessment of treatment tolerability. Magnetic resonance imaging is typically performed annually and when clinical deterioration is suspected, with the goal of detecting subclinical disease activity that might prompt treatment modification. Laboratory monitoring specific to each medication includes complete blood counts, liver function tests, and JC virus antibody testing for patients on natalizumab. Lymphocyte counts require monitoring for medications causing lymphopenia, including fingolimod and dimethyl fumarate. Vaccination status should be addressed before initiating B-cell-depleting therapies, as vaccine responses are blunted during treatment. Treatment failure, evidenced by clinical relapses or significant new MRI lesion activity, should prompt consideration of therapy change to a higher-efficacy agent.

<image>Panel A: Pregnancy and MS timeline showing relapse rate changes during pregnancy and postpartum, with medication considerations for pre-conception through breastfeeding. Panel B: Radiologically isolated syndrome definition with conversion risk factors and management approach options. Panel C: Pediatric MS features including higher early relapse rates, differential diagnosis considerations, and approved medications for adolescents. Panel D: On-therapy monitoring checklist showing clinical assessment frequency, MRI surveillance, and medication-specific laboratory monitoring requirements.</image>

Summary

• Multiple sclerosis is an immune-mediated inflammatory demyelinating disease affecting approximately one million Americans, with three-to-one female predominance and typical onset between ages twenty and forty
• Risk factors include genetics (HLA-DRB1*15:01), Epstein-Barr virus infection, low vitamin D, smoking, and higher latitude residence
• Classic presentations include optic neuritis with painful monocular vision loss, transverse myelitis with sensory level and weakness, and internuclear ophthalmoplegia with impaired adduction
• McDonald criteria require demonstration of dissemination in space across characteristic CNS locations and dissemination in time through either new lesions on follow-up imaging or simultaneous enhancing and non-enhancing lesions
• Brain MRI demonstrates T2-hyperintense lesions in periventricular, juxtacortical, infratentorial, and spinal cord locations; CSF shows oligoclonal bands in eighty-five to ninety-five percent
• Acute relapse treatment consists of high-dose intravenous methylprednisolone; plasma exchange is considered for steroid-refractory severe attacks
• Disease-modifying therapies range from moderate-efficacy injectables to high-efficacy monoclonal antibodies, with early treatment improving long-term outcomes
• Neuromyelitis optica spectrum disorder features aquaporin-4 antibody positivity, longitudinally extensive myelitis, and severe optic neuritis; importantly requires different treatment than MS
• Symptom management addresses fatigue (amantadine, modafinil), spasticity (baclofen, tizanidine), and bladder dysfunction (anticholinergics, intermittent catheterization)

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown